Lu Tse-Min, Ding Yu-An, Charng Min-Ji, Lin Shing-Jong
Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, and School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
Clin Cardiol. 2003 Oct;26(10):458-64. doi: 10.1002/clc.4960261006.
Asymmetrical dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide synthase and has been associated with systemic atherosclerosis; however, the role of ADMA in patients with coronary artery disease (CAD) has not been investigated.
The present study was designed to determine whether the plasma ADMA level predicts the presence of CAD independently, and whether the plasma ADMA level correlates with the extent and severity of coronary atherosclerosis.
In all, 97 consecutive patients with angina and positive exercise stress test were enrolled prospectively for coronary angiography. According to the result of angiography, the subjects were divided into two groups: Group I (n = 46): patients with normal coronary artery or mild CAD (< 50% stenosis of major coronary arteries); Group 2 (n = 51): patients with significant CAD (> or = 50% stenosis of majorcoronary arteries). Plasma levels of ADMA and L-arginine were determined by high-performance liquid chromatography. In addition, we used coronary atherosclerotic score to assess the extent and severity of CAD.
The plasma levels of ADMA in Group 2 patients were significantly higher than those in Group 1 patients (0.66 +/- 0.17 microM vs. 0.44 +/- 0.09 microM, p < 0.001); these were accompanied by significantly lower plasma L-arginine/ADMA ratio in patients with significant CAD (Group 1 vs. 2: 194.0 +/- 55.3 vs. 136.7 +/- 50.3, p < 0.001). In a multivariate stepwise logistic regression analysis, both plasma ADMA level and plasma L-arginine/ADMA ratio were identified as independent predictors for CAD. Moreover, there were significant positive and negative correlations between coronary atherosclerotic score and plasma ADMA level as well as plasma L-arginine/ADMA ratio, respectively (plasma ADMA level: r = 0.518, p < 0.001; L-arginine/ADMA ratio: r = -0.430, p < 0.001).
Both plasma ADMA level and plasma L-arginine/ADMA ratio were useful in predicting the presence of significant CAD and correlated significantly with the extent and severity of coronary atherosclerosis. Our findings suggest that plasma ADMA level may be a novel marker of CAD.
不对称二甲基精氨酸(ADMA)是一氧化氮合酶的内源性竞争性抑制剂,与全身动脉粥样硬化有关;然而,ADMA在冠状动脉疾病(CAD)患者中的作用尚未得到研究。
本研究旨在确定血浆ADMA水平是否能独立预测CAD的存在,以及血浆ADMA水平是否与冠状动脉粥样硬化的程度和严重程度相关。
前瞻性纳入97例连续的心绞痛患者且运动负荷试验阳性,进行冠状动脉造影。根据造影结果,将受试者分为两组:第一组(n = 46):冠状动脉正常或轻度CAD(主要冠状动脉狭窄<50%)的患者;第二组(n = 51):严重CAD(主要冠状动脉狭窄≥50%)的患者。采用高效液相色谱法测定血浆ADMA和L-精氨酸水平。此外,我们使用冠状动脉粥样硬化评分来评估CAD的程度和严重程度。
第二组患者的血浆ADMA水平显著高于第一组患者(0.66±0.17微摩尔/升对0.44±0.09微摩尔/升,p<0.001);严重CAD患者的血浆L-精氨酸/ADMA比值显著降低(第一组对第二组:194.0±55.3对136.7±50.3,p<0.001)。在多因素逐步逻辑回归分析中,血浆ADMA水平和血浆L-精氨酸/ADMA比值均被确定为CAD的独立预测因子。此外,冠状动脉粥样硬化评分与血浆ADMA水平以及血浆L-精氨酸/ADMA比值之间分别存在显著的正相关和负相关(血浆ADMA水平:r = 0.518,p<0.001;L-精氨酸/ADMA比值:r = -0.430,p<0.001)。
血浆ADMA水平和血浆L-精氨酸/ADMA比值均有助于预测严重CAD的存在,并与冠状动脉粥样硬化的程度和严重程度显著相关。我们的研究结果表明,血浆ADMA水平可能是CAD的一种新标志物。